Barclays lowered the firm’s price target on Agilon Health (AGL) to $2 from $5 and keeps an Underweight rating on the shares. The company’s Q3 results underscore the lack of visibility into real-time trends and limited ability to take control of negative developments, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGL:
- Agilon Health downgraded to Market Perform from Outperform at JMP Securities
- Agilon Health price target lowered to $2 from $4 at Deutsche Bank
- Agilon Health downgraded to Market Perform from Outperform at William Blair
- Agilon Health Reports Growth Amidst Financial Challenges
- Agilon Health Reports Revenue Rise Despite Net Loss